SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCAugust 9, 2026

Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients

Radiation therapy combined with durvalumab, given without chemotherapy, produced a two-year progression-free survival rate of 39% in patients with locally advanced non-small cell lung cancer who could not tolerate standard concurrent chemoradiotherapy, according to results of the phase II DART trial published in the Journal of Clinical Oncology.
Share

In brief

  • The single-arm phase II DART trial tested radiation therapy plus concurrent and consolidative durvalumab, without chemotherapy, in 58 patients with inoperable locally advanced non-small cell lung cancer who were ineligible for concurrent chemoradiotherapy because of age, comorbidities, or frailty.
  • The trial met its primary endpoint: two-year progression-free survival was 39% (one-sided CI, 29 to 100), against a target of 36% and a historical benchmark of 20% with sequential chemoradiotherapy.
  • Two-year overall survival was 54%.
  • Grade 3/4 treatment-related adverse events occurred in 12 patients (21%), and grade 5 adverse events occurred in 4 patients (7%): two cases of radiation pneumonitis and two cardiac arrests.
  • Durvalumab was discontinued early because of adverse events in 18 patients (31%), and the median patient age was 82.

Study at a glance

  • Cohort: DART trial, multicenter single-arm prospective phase II study, 58 patients treated per protocol
  • Population: Inoperable locally advanced NSCLC, ineligible for concurrent chemoradiotherapy due to age, comorbidities, or frailty; median age 82 (IQR, 76-86); 28% PD-L1-negative; ECOG 0/1/2 in 7%/79%/14%
  • Treatment: Conventionally fractionated radiation therapy plus concurrent and consolidative durvalumab (1,500 mg fixed dose every 4 weeks, up to 12 months), without chemotherapy
  • Primary endpoint: 2-year progression-free survival of 36% versus a historical 20% with sequential chemoradiotherapy (86% power); met, with an observed 2-year PFS of 39% (one-sided CI, 29 to 100)
  • Survival: 2-year overall survival of 54%
  • Named subgroup: Better performance status and PD-L1 positivity were associated with improved PFS; better ECOG was associated with improved OS; PD-L1 positivity was associated with better cancer-specific survival
  • Safety: Grade 3/4 treatment-related adverse events in 12 patients (21%); grade 5 adverse events in 4 patients (7%), radiation pneumonitis (n=2) and cardiac arrest (n=2); durvalumab discontinued early for adverse events in 18 patients (31%)

No standard treatment exists for locally advanced NSCLC patients too frail for chemoradiotherapy

Concurrent platinum-based chemotherapy and radiation therapy, followed by consolidative durvalumab, is the standard of care for fit patients with inoperable, locally advanced non-small cell lung cancer. No standard of care exists for patients who cannot tolerate that regimen because of age, comorbidities, or frailty. The DART trial investigated whether concurrent and consolidative durvalumab given with definitive radiation therapy alone, without chemotherapy, could offer these patients an effective option.

A 58-patient, single-arm phase II trial of radiation and durvalumab without chemotherapy

DART was a multicenter, single-arm, prospective phase II trial. Patients received conventionally fractionated radiation therapy plus concurrent and consolidative durvalumab at a fixed dose of 1,500 mg every 4 weeks, for up to 12 months. The primary endpoint was set at a 2-year progression-free survival rate of 36%, against a historical benchmark of 20% with sequential chemoradiotherapy, powered at 86%.

Fifty-eight patients were treated per protocol. The median age was 82 (interquartile range, 76 to 86). Twenty-eight percent of patients were PD-L1-negative. By performance status, 7% had an ECOG score of 0, 79% had a score of 1, and 14% had a score of 2, a population skewed toward the older, lower-performance-status patients the trial was designed to serve.

The trial cleared its benchmark: 39% two-year progression-free survival against a 20% historical rate

The study met its primary endpoint. Two-year progression-free survival was 39% (one-sided confidence interval, 29 to 100), above both the 36% target and the 20% historical rate with sequential chemoradiotherapy. Two-year overall survival was 54%. Better performance status and PD-L1 positivity were associated with improved progression-free survival; better ECOG score was associated with improved overall survival; and PD-L1 positivity was associated with better cancer-specific survival.

The trial reports these results against a historical comparator rather than a randomized control arm, since it enrolled a single group of patients rather than randomizing between durvalumab-plus-radiation and an alternative regimen.

Grade 5 adverse events occurred in 7% of patients, including two cardiac arrests

Grade 3/4 treatment-related adverse events occurred in 12 patients (21%). Grade 5 adverse events, the most severe grade, occurred in 4 patients (7%): two cases of radiation pneumonitis and two cardiac arrests. Durvalumab was discontinued early because of adverse events in 18 patients (31%), just under a third of the cohort, in a population whose median age was 82.

“Thoracic RT with concurrent and consolidative durvalumab is a promising treatment option for cCRT-ineligible patients with LA-NSCLC, demonstrating better PFS with a favorable safety profile compared with historical controls.”Rimner et al., Journal of Clinical Oncology (2026)

A single-arm result measured against history, not a randomized comparator

DART’s primary endpoint was met against a historical benchmark rather than a concurrently randomized control group, and the trial enrolled 58 patients at a single treatment stage rather than following a larger cohort past 2 years. The paper does not report median progression-free or overall survival in months, an objective response rate, or outcomes beyond the 2-year mark, so how the benefit holds up over a longer follow-up, and how it would compare in a randomized trial against a different chemotherapy-free regimen, are not established by this study.

Sources

  1. Journal of Clinical Oncology. Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART) (2026-07-16). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Charles Rudin.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nov 16 2026
RESEARCH
Immunotherapies

Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma

J. RemonN. GirardN. Reguart
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi